Science and Enterprise

Category: Joint ventures/collaborations

  • Bristol-Myers, Vanderbilt to Partner on Parkinson’s Drugs

    Pharmaceutical company Bristol-Myers Squibb and Vanderbilt University in Nashville will collaborate on new treatments for Parkinson’s disease, a progressive brain disorder. The financial magnitude and length of the multi-year agreement were not disclosed. Under the deal, Vanderbilt’s Center for Neuroscience Drug Discovery will identify drug candidates from current research being supported by the Michael J.…

  • Tilted Screen Displays Developed for Mobile Devices

    Computer scientists at University of Bristol and Lancaster University in the U.K. and Nokia Research Center in Tampere, Finland created a display technology that can physically adjust parts of the screen at different angles to provide more dramatic 3-D effects. The developers of the Tilt Displays, as the screen is called, will discuss the technology…

  • Pharmas to Collaborate on Improving Clinical Trial Process

    Ten of the world’s larger pharmaceutical companies formed a non-profit organization to improve the way clinical drug studies, a major time and financial expense, are conducted. Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech (a division of the Roche Group), and Sanofi will take part in the…

  • Purdue, Adobe Create Process to Strengthen 3-D Print Objects

    Computer scientists at Purdue University in Indiana and computer software company Adobe Systems devised an automated process to add more robustness to objects created through three-dimensional printing. The researchers discussed their methods in a presentation last month at the SIGGRAPH 2012 conference in Los Angeles. 3-D printers create shapes by adding various materials layer-by-layer, including…

  • Trial Shows Vaccine Effective Against Most Dengue Viruses

    A clinical trial by researchers from the pharmaceutical company Sanofi Pasteur, with clinicians and public health officers from Thailand, shows a candidate vaccine to prevent the tropical disease dengue fever was effective against three of the four dengue viruses. The findings from the trial, funded by the Dengue Vaccine Initiative, appear online in the journal…

  • Cambridge, GSK to Develop Therapies for Lung/Liver Disorder

    University of Cambridge in the U.K. will partner with the global pharmaceutical company GlaxoSmithKline to discover and develop new medicines to treat a genetic disease affecting the lungs and liver. The university is expected to receive an upfront payment, and is eligible for milestone payments and royalties under the agreement, but the amounts of those…

  • University Consortium to Research Nanotech Health Monitors

    North Carolina State University in Raleigh will lead a group of universities in the U.S., Australia, and Asia to develop self-powered health monitoring sensors and devices. Some 30 industry partners are expected to join the five-year, $18.5 million consortium, known as the Center for Advanced Self-Powered Systems of Integrated Sensors and Technologies (ASSIST), and funded…

  • University to Develop, Commercialize HIV/AIDS Nanomedicines

    Researchers at University of Liverpool in the U.K. are developing nanoscale therapies to treat HIV and AIDS, and collaborating with a company to take the drugs to market. The project is funded by a £1.65 million ($US 2.61 million) grant from the U.K.’s Engineering and Physical Sciences Research Council. The aim of the project is…

  • Janssen Licenses Biotech’s Antibody for Multiple Myeloma

    Janssen Pharmaceutical Companies, a division of Johnson & Johnson in Horsham, Pennsylvania, agreed to license a cancer drug targeting multiple myeloma made by biotechnology company Genmab A/S in Copenhagen, Denmark. The agreement has a total potential value of $1.1 billion from upfront, milestone, and royalty payments, as well as an equity investment in Genmab. The…

  • Biopharm, Monsanto to Partner on Agricultural Biotechnology

    Alnylam Pharmaceuticals Inc. in Cambridge, Massachusetts and Monsanto Company in St. Louis, will collaborate on developing biotechnology applications in agriculture. The agreement has an immediate value to Alnylam of $29.2 million. The 10-year agreement gives Monsanto exclusive rights worldwide to use Alnylam’s platform technology and intellectual property in the field of agriculture. Alnylam is a…